Advertisement

Neurological Sciences

, Volume 38, Issue 5, pp 727–743 | Cite as

Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann–Pick type C disease: review of initial published cases

  • Juan Eduardo Megías-Vericat
  • Ana García-Robles
  • María José Company-AlbirEmail author
  • María José Fernández-Megía
  • Francisco Carlos Pérez-Miralles
  • Eduardo López-Briz
  • Bonaventura Casanova
  • José Luis Poveda
Review Article

Abstract

Niemann–Pick type C (NP-C) is a rare neurodegenerative disorder. Management is mainly supportive and symptomatic. The investigational use of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) showed a promising role in treating NP-C, although efficacy and safety have not been established. We conducted searches of MEDLINE, Cochrane, EMBASE, and other databases of reported cases of HP-β-CD compassionate use in NP-C disease. Sixteen reported cases were eligible, including evaluable information of 17 patients. The median onset age of HP-β-CD was 14 years (range 2–49 years). Intrathecal route was employed in 16 patients, in 3 patients simultaneously to IV infusions. Intracerebroventricular route was used in two patients. An objective improvement of clinical outcomes was measured in 14 patients, mainly by the NIH NP-C Clinical Severity Score and brainstem auditory evoked potential. Besides, an increase in metabolism and activities of the brain were observed in image tests and cholesterol biomarkers. Most patients showed some clinical benefit or a stabilization of NP-C progression. There were 17 adverse events (AEs) reported in 11 patients, 11 of them related to the drug and 6 to the route of administration. Loss of hearing was reported in four patients. The most severe AE were fever and chemical meningitis. Results suggest that efficacy may be partial and dependent on the early administration of the drug, the severity of the disease, and interpersonal variability. HP-β-CD could help stabilize NP-C with low toxicity potential, although some AEs have been reported. Moreover, controlled clinical trials would be necessary to evaluate the role of HP-β-CD in NP-C.

Keywords

Niemann–Pick 2-Hydroxypropyl-β-cyclodextrin Effectiveness Toxicity 

Notes

Acknowledgements

The authors wish to thank Drs. Caroline Hastings, Elizabeth Berry-Kravis, Muneaki Matsuo, Ana Valle, Mª Jesús Esteban, Sonia Cruz, Y Sakiyama, and Begoña Arias for the additional information about their patients. We are grateful to Mr. Luis González for his editorial assistance on this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5:16. doi: 10.1186/1750-1172-5-16 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mengel E, Klünemann H-H, Lourenço CM, Hendriksz CJ, Sedel F, Walterfang M et al (2013) Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis 8:166. doi: 10.1186/1750-1172-8-166 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Patterson M (2013) Niemann-Pick Disease Type C. GeneReviews®. University of Washington. http://www.ncbi.nlm.nih.gov/books/NBK1296/. Accessed 06 May 2016
  4. 4.
    Alobaidy H (2015) Recent advances in the diagnosis and treatment of Niemann-Pick disease type c in children: a guide to early diagnosis for the general pediatrician. Int J Pediatr 2015:e816593. doi: 10.1155/2015/816593 CrossRefGoogle Scholar
  5. 5.
    Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, NP-C Guidelines Working Group (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106(3):330–344. doi: 10.1016/j.ymgme.2012.03.012 CrossRefGoogle Scholar
  6. 6.
    Orphanet: An online database of rare diseases and orphan drugs. Copyright, 1997. Available INSERM http://www.orpha.net. Accessed 06 May 2016
  7. 7.
    Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H et al (2013) Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 8:12. doi: 10.1186/1750-1172-8-12 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Josephs KA, Gerpen MWV, Gerpen JAV (2003) Adult onset Niemann-Pick disease type C presenting with psychosis. J Neurol Neurosurg Psychiatry 74(4):528–529. doi: 10.1136/jnnp.74.4.528 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lyseng-Williamson KA (2014) Miglustat: a review of its use in Niemann-Pick disease type C. Drugs 74(1):61–74. doi: 10.1007/s40265-013-0164-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M et al (2014) Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 14(3):330–339. doi: 10.2174/1568026613666131127160118 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy J (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. Proc Natl Acad Sci USA 106(7):2377–2382. doi: 10.1073/pnas.0810895106 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Liu B, Ramirez CM, Miller AM, Repa JJ, Turley SD, Dietschy JM (2010) Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J Lipid Res 51(5):933–944. doi: 10.1194/jlr.M000257 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ramirez CM, Liu B, Taylor AM, Repa JJ, Burns DK, Weinberg AG et al (2010) Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr Res 68(4):309–315. doi: 10.1203/00006450-201011001-00604 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ward S, O’Donnell P, Fernandez S, Vite CH (2010) 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res 68(1):52–56. doi: 10.1203/00006450-201011001-00099 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K et al (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4(9):e6951. doi: 10.1371/journal.pone.0006951 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vite CH, Bagel JH, Swain GP, Prociuk M, Sikora TU, Stein VM et al (2015) Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Sci Transl Med 7(276):276ra26. doi: 10.1126/scitranslmed.3010101
  17. 17.
    Aqul A, Liu B, Ramirez CM, Pieper AA, Estill SJ, Burns DK, Repa JJ, Turley SD, Dietschy JM (2011) Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J Neurosci 31(25):9404–9413. doi: 10.1523/JNEUROSCI.1317-11.2011 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    FDA letter from Dr. Timothy Cote and OOPD (2010) Designation Request# 10-3039Google Scholar
  19. 19.
    European Medicines Agency(2015) Public summary of opinion on orphan designation EMA/COMP/546608/2011.2010. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/09/WC500112733.pdf. Accessed 06 May 2016
  20. 20.
    Pontikis CC, Davidson CD, Walkley SU, Platt FM, Begley DJ (2013) Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood–brain barrier permeability. J Inherit Metab Dis 36(3):491–498. doi: 10.1007/s10545-012-9583-x CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Eunice Kennedy Shriver National Institute of Child Health and Human Development (2014) NCT01747135. Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease. ClinicalTrials.gov. National Institutes of Health Clinical Center. https://clinicaltrials.gov/ct2/show/NCT01747135. Accessed 06 May 2016
  22. 22.
    Vtesse Inc. (2015) NCT02534844. Study of 2-hydroxypropyl-β-cyclodextrin (VTS-270) to Treat Niemann-Pick Type C1 (NPC1) Disease. ClinicalTrials.gov. National Institutes of Health Clinical Center. https://clinicaltrials.gov/ct2/show/ NCT02534844. Accessed 06 May 2016
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135 CrossRefGoogle Scholar
  24. 24.
    Hastings C, Torkildson J, Raphael R (2012) Intrathecal hydroxy-propyl-beta-cyclodextrin reverses hearing loss in identical twin girls with Niemann-Pick type C disease. Mol Genet Metab 105(2):S34. doi: 10.1016/j.ymgme.2011.11.072 CrossRefGoogle Scholar
  25. 25.
    Hastings C (2010) Request for intrathecal delivery of HPBCD for Niemann Pick Type C patients, Caroline Hastings, M.D. Principal Investigator Department of Pediatric Hematology Oncology Children’s Hospital and Research Center Oakland Submission Date to FDA: August 13, 2010. http://addiandcassi.com/wordpress/wp-content/uploads/Hempel-Cyclodextrin-Intrathecal-FDA-Filing-2010-Aug.pdf. Accessed 06 May 2016
  26. 26.
    Berry-Kravis E, O’Keefe J, Pounardjian, Chin J, Porter FD, Ory D, et al. (2014) Intermediate size patient population IND for 2-hydroxypropyl-cyclodextrin (HP-CD) outpatient treatment of siblings with Niemann-Pick type C1 (NP-C1) and disparate rates of progression: exploration of outcome measures and biomarkers. Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research June 12-14, 2014. Abstract 6:17. https://niemannpick.nd.edu/assets/135126/2014abstractbooklet.pdf. Accessed 06 May 2016
  27. 27.
    Berry-Kravis E, O’Keefe J, Pounardjian T, Chin J, Porter FD, Ory D et al (2014) Intermediate size patient population IND for 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) outpatient treatment of siblings with Neimann–Pick type C1 (NP-C1) and disparate rates of progression: exploration of outcome measures and biomarkers. Ann Neurol 76(s18):S215–S216. doi: 10.1002/ana.24226 Google Scholar
  28. 28.
    Berry-Kravis E, O’Keefe J, Hoffmann A, Winston A, LaGorio L, Robertson E et al (2015) Objective clinical efficacy outcome measures for cyclodextrin treatment in Niemann-Pick type C (NP-C): a five-domain approach. michael, marcia, and christa parseghian scientific conference for Niemann-Pick type C research June 11–13, 2015. Abstract 13:23. https://niemannpick.nd.edu/assets/168424/2015abstractbooklet.pdf. Accessed 06 May 2016
  29. 29.
    Maarup TJ, Chen AH, Porter FD, Farhat NY, Ory DS, Sidhu R et al (2015) Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1. Mol Genet Metab 116(1–2):75–79. doi: 10.1016/j.ymgme.2015.07.001 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cruz-Pardos S, García-Poza P, Sánchez-García FJ (2013) Treatment with cyclodextrin for Niemann-Pick s disease (Article in Spanish). Farm Hosp 37(3):271–272. doi: 10.7399/FH.2013.37.3.555 PubMedGoogle Scholar
  31. 31.
    Valle AM, González MC, Morón R, Ruiz S, Cabeza J (2015) Hydroxypropyl-beta cyclodextrin in Niemann-Pick type C disease. Int J Clin Pharm 37(1):282. doi: 10.1007/s11096-014-0039-2 Google Scholar
  32. 32.
    Rodríguez R, De Santos MT, Natera D, Fernández MI, Grasa CD, Taboas A et al (2015) Nuevas expectativas de tratamiento de Niemann pick tipo C [Article in Spanish] XXXVIII Anual Meeting SENEP: abstract PO 147. http://www.senep2015.com/images/site/comunicaciones_aceptadas/Posters_Orales.pdf. Accessed 06 May 2016
  33. 33.
    García-Robles AA, Company-Albir MJ, Megías-Vericat JE et al (2016) Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann-Pick type C patients. J Neurol Sci 15(366):65–67. doi: 10.1016/j.jns.2016.04.048 CrossRefGoogle Scholar
  34. 34.
    Vieira C (2011) The use of Cyclodextrin in Niemann-Pick Type C disease in two girls: Report after one year of treatment. Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann- Pick Type C Research June 9–11, 2011. Abstract 28:28. https://niemannpick.nd.edu/assets/52702/all_abstracts.pdf. Accessed 06 May 2016
  35. 35.
    Vieira C, Lucena R (2012) Use of cyclodextrin in two Brazilian girls with Niemann-Pick type C: intrathecal report. Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann- Pick Type C Research June 7–9, 2012. Abstract 10:18. https://niemannpick.nd.edu/assets/69394/abstracts_in_speaking_order.pdf. Accessed 06 May 2016
  36. 36.
    Vieira C, Jagersbacher JB, Dórea I, Costa F and Lucena R (2014) Use of cyclodextrin in two Brazilian girls with Niemann-Pick disease type C. ICNC, 2. Neurogenetics (P338-P372). JICNA, 1(Suppl I);124. doi:http://dx.doi.org/10.17724/jicna.2014.s1.pos12
  37. 37.
    Matsuo M, Togawa M, Hirabaru K, Mochinaga S, Narita A, Adachi M et al (2013) Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Mol Genet Metab 108(1):76–81. doi: 10.1016/j.ymgme.2012.11.005 CrossRefPubMedGoogle Scholar
  38. 38.
    Matsuo M, Shraishic K, Wadad K, Ishitsukac Y, Doia H, Maedab M et al (2014) Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann-Pick Type C disease. Mol Genet Metab Rep 1:391–400. doi: 10.1016/j.ymgmr.2014.08.004 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sakiyama Y, Shibata S, Sanayama H, Ono S, Maekawa M, Matsuo M et al (2015) Intrathecal 2-hydroxypropyl-beta-cyclodextrin (HPBCD) therapy in adult-onset Niemann-Pick disease type C (NPC). J Neurol Sci 357(S1):e20. doi: 10.1016/j.jns.2015.08.719 Google Scholar
  40. 40.
    Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK et al (2010) Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 153B(1):132–140. doi: 10.1002/ajmg.b.30969 PubMedPubMedCentralGoogle Scholar
  41. 41.
    Iturriaga C, Pineda M, Fernández-Valero EM, Vanier MT, Coll MJ (2006) Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci 249(1):1–6. doi: 10.1016/j.jns.2006.05.054 CrossRefPubMedGoogle Scholar
  42. 42.
    Porter FD, Yanjanin N, Liu A, Shankar R, Ory D, Pavan B et al (2014) Therapeutic trials for Niemann-Pick disease, type C1: 2-hydroxypropyl-β-cyclodextrin. Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research June 12-14, 2014. Abstract 7:18. https://niemannpick.nd.edu/assets/135126/2014abstractbooklet.pdf. Accessed 06 May 2016
  43. 43.
    Liu B, Li H, Repa JJ, Turley SD, Dietschy JM (2008) Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 49:663–669. doi: 10.1194/jlr.M700525-JLR200 CrossRefPubMedGoogle Scholar
  44. 44.
    Vite C, Mauldin E, Ward S, Stein V, Prociuk M, Haskins ME et al (2011) Intrathecal cyclodextrin therapy of feline Niemann-Pick Type C disease. Mol Genet Metab 102:S44. doi: 10.1016/j.ymgme.2010.11.148 CrossRefGoogle Scholar
  45. 45.
    Porter FD, Farhat NY, Ottinger EA, McKew JC, Weissfeld L, Machielse B et al (2016) 1/2 evaluation of intrathecal 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease type C1. Mol Genet Metab 117:S97. doi: 10.1016/j.ymgme.2015.12.411 CrossRefGoogle Scholar
  46. 46.
    Sidhu R, Jiang H, Farhat NY, Carrillo-Carrasco N, Woolery M, Ottinger E et al (2015) A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J Lipid Res 56(6):1222–1233. doi: 10.1194/jlr.D058487 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Committee for Human Medicinal Products (CHMP), European Medicines Agency (EMA). Background review for cyclodextrins used as excipients. In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’. 2014. (CPMP/463/00 Rev. 1). http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500177936.pdf. Accessed 06 May 2016
  48. 48.
    Cronin S, Lin A, Thompson K, Hoenerhoff M, Duncan RK (2015) Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin. J Assoc Res Otolaryngol 16(5):599–611. doi: 10.1007/s10162-015-0528-6 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia 2017

Authors and Affiliations

  • Juan Eduardo Megías-Vericat
    • 1
  • Ana García-Robles
    • 1
  • María José Company-Albir
    • 1
    Email author
  • María José Fernández-Megía
    • 1
  • Francisco Carlos Pérez-Miralles
    • 2
  • Eduardo López-Briz
    • 1
  • Bonaventura Casanova
    • 2
  • José Luis Poveda
    • 1
  1. 1.Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La FeValenciaSpain
  2. 2.Unidad Mixta de Esclerosis Múltiple y NeurorregeneraciónIIS Hospital La Fe, Universitat de València, Hospital Universitari i Politècnic La FeValenciaSpain

Personalised recommendations